Pharmacy

After legal battles and lobbying efforts, tens of thousands of people with hepatitis C are gaining earlier access to expensive drugs that can cure this condition.

Anthem and its pharmacy manager Express Scripts overcharged patients with job-based insurance for prescription drugs, alleges a lawsuit that seeks class action status for what could be tens of thousands of Americans.

With more than 350 oncology researchers, data and technology experts, alongside with more 6,000 people at linked events nationwide, it's billed as the the first time a group this big has gathered for such an initiative.

As advocates seek an all-hands-on-deck response to the nation's opioid crisis, many physicians are calling on federal authorities to change these satisfaction surveys.

Drugmakers are waging a fierce campaign against a proposed California law that would require them to justify the costs of their treatments and disclose major price hikes.

Boosting support for prescription drug monitoring programs, and establishing a consistent funding source, is strongly related to a reduction in opioid-related overdose deaths, says a new study from Health Affairs.

Ruling ensures patent challengers may make an appeal before a U.S. Patent and Trademark Office board, rather than to the federal court.

To cure the country's opioid addiction crisis, collaboration on aligned incentives is needed between insurers, providers and the pharmaceutical industry, Cigna CEO and President David Cordani said during the America's Health Insurance Plans conference in Las Vegas last week.

In an analysis presented Tuesday, the California Public Retirement System's staff lauded the goal of controlling prescription drug prices, but it warned of possible resistance -- or even retaliation -- by pharmaceutical companies. The CalPERs staff also noted that implementation of the drug price proposition could unravel the whole purchasing and distribution network the agency has in place.

In its June report to Congress, the Medicare Payment Advisory Commission warned that rising drug costs and other factors have helped drive Medicare Part D spending up nearly 60 percent from 2007 to 2014.